NewswireToday - /newswire/ -
Vancouver, British Columbia, Canada, 2013/06/10 - GE Healthcare announced that it has received FDA clearance of its latest Xeleris† Processing and Review workstation software, adding to one of the most innovative suites of Molecular Imaging solutions in the industry.. NYSE: GE
Today at the Society of Nuclear Medicine and Molecular Imaging meeting, GE Healthcare announced that it has received FDA clearance of its latest Xeleris† Processing and Review workstation software, adding to one of the most innovative suites of Molecular Imaging solutions in the industry.
The latest release of Xeleris enables automation, personalization, access and advanced applications. Nuclear Medicine clinicians will gain access to specific image results where and when they are needed. The availability of Xeleris applications extends not only to GE Centricity PACS systems and Xeleris Floating clients (XFL), but now includes an open application for virtually any PACS and the GE AW Server workstation environment.
“I’m excited to present the new Xeleris to our customers,” said Nathan Hermony, General Manager, Nuclear Medicine, GE Healthcare. “The personalized workflow and unique new clinical applications will give clinicians the information they demand with speed, convenience and flexibility.”
The new Xeleris release includes next generation of DaTQUANT**, which enables visual evaluation and quantification of 123I Ioflupane images and comparison to values in a normal population database. This application provides tools to analyze dopaminergic neuron terminal binding and differences between multiple scans, comparison with a user-chosen database of suitable age-matched reference values, and may provide adjunct information to physicians assessing patients for Parkinson’s disease.
Hermony added,“GE continues to bring innovative products to meet not only the technical, but also the clinical needs of the Molecular Imaging community. As healthcare continues to evolve, we are a family of businesses in a unique position to deliver value in personalized disease management strategies.”
* Trademark of General Electric Company
** DaTQUANT is available for sale only for countries where Ioflupane (I123) pharmaceutical is approved for use. It is not available for sale in Canada.
† Xeleris 3.1 is not available for sale in Canada and has not yet been licensed by Health Canada. Xeleris 3.1 is not commercially available for sale in every region.